Fulgent Genetics, a technology-driven company specializing in laboratory services and therapeutic development, secured a five-year contract with the U.S. Department of Veterans Affairs (VA). This contract will provide Veterans access to hereditary cancer, pharmacogenetic, and other genetic tests. Fulgent has a history of providing both clinical and research-based genetic testing services to the VA since 2017. This new agreement expands those services, specifically enabling access to hereditary cancer tests for individuals with cancer or a family history of certain cancers.

A significant contract component involves pharmacogenetic testing, which uses genomic information to personalize medicine by predicting patient responses to specific medications. This personalized approach allows for more effective treatment strategies tailored to individual genetic profiles. The contract also highlights Fulgent’s strengths in bioinformatics, quality, and turnaround time, solidifying its position as a valuable partner to the VA.

Fulgent’s comprehensive suite of germline tests allows them to create custom solutions tailored to the VA’s specific requirements. Pharmacogenetic (PGx) testing, in particular, has become important for patient care. Fulgent’s PGx test utilizes next-generation sequencing, providing higher resolution and broader coverage for accurate and actionable data. This advanced technology ensures the delivery of reliable results that can directly inform treatment decisions.

This five-year contract is valued at up to $99 million and covers hereditary cancer and pharmacogenetic testing. This significant investment underscores the VA’s commitment to providing Veterans with cutting-edge healthcare services. It’s important to note that the U.S. Department of Veterans Affairs doesn’t endorse any specific statements within this announcement. The information provided is solely the responsibility of Fulgent Genetics.

Fulgent is transitioning from primarily a genomic diagnostic company into a fully integrated precision medicine company. This evolution reflects their expanding focus beyond diagnostics and into therapeutic development. Their therapeutic development business works on drug candidates for various cancers using a novel nanoencapsulation and targeted therapy platform. This platform aims to improve the effectiveness and safety of both new and existing cancer drugs.

Source link: http://www.businesswire.com/news/home/20241031083467/en/Fulgent-Genetics-Awarded-Contract-by-the-U.S.-Department-of-Veterans-Affairs-to-Provide-Hereditary-Cancer-Pharmacogenetic-and-Other-Genetic-Testing-to-Veterans1

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.